AZTRHealthcare · BiotechnologyAZTR Stock Forecast: Azitra, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Azitra, Inc. hold a median 12-month price target of $0.78 — +484.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
AZTR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Azitra, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Azitra, Inc. — and when they’d sell — is the membership.
AZTR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AZTR, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +484.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2025 | Maxim Group | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AZTR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Azitra, Inc. (AZTR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 0.2×
- EV / EBITDA
- 0.6×
Cheaper than 74% of US stocks
Cheaper than 89% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −158.7%
- Return on assets
- −81.8%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
AZTR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AZTR appears on the weeks it earns a place.
Frequently asked questions about AZTR stock
What is the AZTR stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Azitra, Inc. have a median 12-month price target of $0.78, with estimates ranging from $0.55 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AZTR stock a buy right now?
Of the 1 analysts covering Azitra, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Azitra, Inc. 29 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AZTR?
As at 1 Aug 2026, Azitra, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
Will AZTR stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +484.0% from the last close, and Ticker Nerd's factor model ranks Azitra, Inc. 29 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AZTR stock forecast for 2030?
No analyst covering Azitra, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.55 to $1 over the next 12 months.
What does Azitra, Inc. do?
Azitra Inc. is a clinical-stage biotechnology company that focuses on harnessing the therapeutic potential of the human microbiome.
About Azitra, Inc.
Azitra Inc. is a clinical-stage biotechnology company that focuses on harnessing the therapeutic potential of the human microbiome. The company is dedicated to developing microbiome-based treatments to address dermatological conditions and improve skin health. Azitra leverages its proprietary platform to design therapies that utilize commensal microbiota, which are the naturally occurring bacteria on human skin, for combating various skin diseases. By targeting skin-associated microbiomes, Azitra aims to create safe and effective treatment options for conditions that may not respond well to conventional treatments. Its innovative approach positions Azitra in the emerging field of microbiome therapy, impacting healthcare and dermatology industries. With its specialized focus, Azitra plays a significant role in advancing biotechnology innovations and contributing to the evolving narrative of precision medicine and personalized healthcare.
CEO Mr. Francisco D. Salva · 13 employees · United States · https://azitrainc.com